JAB-23E73
Sponsors
Jacobio Pharmaceuticals Co., Ltd.
Conditions
Advanced Solid TumorAdvanced Solid Tumors
Phase 1
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
RecruitingNCT06959615
Start: 2024-11-22End: 2027-08-31Target: 334Updated: 2026-01-20
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RecruitingNCT06973564
Start: 2025-05-29End: 2028-02-01Target: 294Updated: 2026-01-16